HIPO trades 18.7% above Wall Street's consensus target of $28.38.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HIPO achieves its forward estimates and maintains a stable P/E multiple of 25.8x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Hippo Holdings Inc. (HIPO) has a Wall Street consensus price target of $28.38, based on estimates from 6 covering analysts. With the stock currently trading at $34.89, this represents a potential downside of -18.7%. The company has a market capitalization of $908M.
Analyst price targets range from a low of $17.50 to a high of $45.00, representing a 97% spread in expectations. The median target of $25.50 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, HIPO trades at a trailing P/E of 29.5x and forward P/E of 25.8x. Analysts expect EPS to grow +14.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $23.33, with bear and bull scenarios of $14.70 and $30.74 respectively. Model confidence stands at 64/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LMNDLemonade, Inc. | $3.0B | $39.55 | $66.00 | +66.9% | Buy | — | 15 |
 ROOTRoot, Inc. | $608M | $43.37 | $54.00 | +24.5% | Hold | 9.5x | 14 |
 KINSKingstone Companies, Inc. | $296M | $20.46 | — | — | Buy | 7.6x | 4 |
 HGTYHagerty, Inc. | $6.2B | $17.97 | $17.00 | -5.4% | Buy | 257.8x | 7 |
 SLNGStabilis Solutions, Inc. | $67M | $3.58 | — | — | Buy | — | 1 |
 ALLThe Allstate Corporation | $65.6B | $254.81 | $266.31 | +4.5% | Hold | 7.1x | 45 |
 TRVThe Travelers Companies, Inc. | $82.4B | $395.20 | $356.18 | -9.9% | Hold | 10.8x | 44 |
 CBChubb Limited | $141.6B | $365.02 | $355.91 | -2.5% | Buy | 12.5x | 44 |
 HIGThe Hartford Insurance Group, Inc. | $36.7B | $133.99 | $145.40 | +8.5% | Buy | 10.3x | 42 |
 UPCUniverse Pharmaceuticals Inc. | $783040 | $1.39 | — | — | — | — | — |
Quick answers to the most common questions about buying HIPO stock.
HIPO's consensus price target is $28.38, -18.7% below the current price of $34.89. The 6 analysts tracking HIPO see downside risk at present valuations.
HIPO has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $28.38 implies -18.7% downside from current levels.
HIPO trades at a forward P/E of 25.8444x, representing a moderate valuation. With analysts targeting $28.38 (-18.7% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $45 for HIPO, while the most conservative target is $17.5. The consensus of $28.38 represents the median expectation. Our quantitative valuation model projects a bull case target of $31 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
HIPO is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HIPO stock forecast based on 6 Wall Street analysts shows a consensus price target of $28.38, with estimates ranging from $17.5 (bear case) to $45 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $23, with bear/bull scenarios of $15/$31.
Our quantitative valuation model calculates HIPO's fair value at $23 (base case), with a bear case of $15 and bull case of $31. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 64/100.
HIPO trades at a forward P/E ratio of 25.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 29.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on HIPO, with 0 Sell ratings and a price target of $28.38 (-18.7% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HIPO analyst price targets range from $17.5 to $45, a 97% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $28.38 consensus represents the middle ground. Our model's $15-$31 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.